LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday it has begun shipping doses of its flu vaccine Fluarix Quadrivalent to US healthcare providers, and has also received licence approval for its other vaccine Flulaval Quadrivalent.
The company expects to begin shipping Flulaval Quadrivalent in August, and expects to supply an estimated 32 to 38 million doses of both vaccines across the US for the 2015-16 flu season.
In the previous season Glaxo shipped around 27 million doses. The vaccines are both four-strain vaccines, and Glaxo said it had decided to switch to supplying 100% four-strain vaccines after customer demand in the previous flu season and early pre-booking for the upcoming season.
Shares in Glaxo were flat at 1,382.50 pence Thursday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
